Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: This paper surveys the actuarial techniques connected with salary scale mathematics for the valuation of defined benefit pension plans. Followed by several discussion papers submitted

Description: The session offers high-level initial steps to get started using R, as well as a list of helpful resources for both general data science and actuarial science with R. Attendees will learn about popular R packages to perform practical tasks such as importing, transforming and visualizing data, as well as packages commonly used by actuaries. You will also be introduced to the markdown package for creating reproducible and reusable analyses and workflows. By the end of the session, you will be familiar enough with using R and RStudio to begin incorporating these tools in your day-to-day work as an actuary

Description: Learn how modernization of data, models, and technology are influencing workflows. This webcast will address how workflows are changing in response to new regulatory requirements and the impacts the changes have on modeling and end-to-end future state operating models. Industry leading actuaries will discuss: How team collaboration can increase quality and speed of reporting to internal and external stakeholders How to strengthen controls and compliance frameworks across finance and actuarial departments How to modernize actuarial input/output for strategic analysis and insights How to attract and retain top talent by improving opportunities for actuaries There will also be dedicated time to ask questions of those who have made the transition.

Description: Chapter 1 presents the background to the current study, followed by the methodology used, and a summary of the findings of the study. From Group Medical Insurance Large Claims Database Collection and Analysis, M-HB97-1.

Description: Discussion of a newly released LTC experience study, including description of data and its increased scope compared to the prior report, reporting specifications, and findings.

Description: In this paper the author proposes a proof for new formulas that derive exposure formulas of the valuation-schedule type on the basis of the Balducci assumption. In addition he provides a short cut for the coefficients of the terms involving deaths. Then he derives a general exposure formula of the valuation-schedule type that may be used for all mortality studies with an observation period covering an integral number of consecutive years. From ACTUARIAL RESEARCH CLEARING HOUSE, 1980 VOL. 2.

Description: This paper presents formulas for the L-Function and shows this function has applications in computing survival rates free from the influence of a given cause of death.

Description: The attached report presents the results of a survey conducted by the Society of Actuaries Mortality and Underwriting Survey Committee in July of 2008 under the following categories: 1. Modeling Mortality Risk. 2. Use of Reinsurance to Manage Mortality. 3. Retention / Large Case Management. 4. Catastrophe Reinsurance. 5. Mortality Concentration of Risk. 6. Catastrophic Bonds.

Description: Universal Life with Secondary Guarantees (ULSG) was first introduced in the late 1990's as low-cost, long-term death benefit protection. As this business ages, writers are experiencing pressured earnings from emerging experience, secondary markets for insurance products and low interest rates. In response, writers are sharpening their pencils on experience analysis and risk management with an eye for opportunities to increase the performance of their blocks.